New York State Teachers Retirement System Buys 394 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

New York State Teachers Retirement System boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,120 shares of the specialty pharmaceutical company’s stock after acquiring an additional 394 shares during the quarter. New York State Teachers Retirement System owned 0.12% of ANI Pharmaceuticals worth $1,439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in shares of ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after purchasing an additional 10,716 shares during the period. Texas Permanent School Fund Corp raised its holdings in ANI Pharmaceuticals by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after buying an additional 172 shares during the last quarter. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $106,000. Swiss National Bank grew its holdings in ANI Pharmaceuticals by 7.7% in the 1st quarter. Swiss National Bank now owns 32,300 shares of the specialty pharmaceutical company’s stock worth $2,233,000 after acquiring an additional 2,300 shares during the last quarter. Finally, Sei Investments Co. increased its position in shares of ANI Pharmaceuticals by 16.4% in the first quarter. Sei Investments Co. now owns 11,321 shares of the specialty pharmaceutical company’s stock valued at $783,000 after acquiring an additional 1,594 shares during the period. 76.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, Raymond James boosted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $61.44 on Friday. The business’s fifty day moving average is $58.66 and its 200 day moving average is $61.52. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 52.51 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a twelve month low of $48.20 and a twelve month high of $70.81.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.